Skip Navigation


Annals of Oncology Advance Access originally published online on November 17, 2005
Annals of Oncology 2006 17(5):750-762; doi:10.1093/annonc/mdj083
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 4 iss...
Right arrow All Versions of this Article:
17/5/750    most recent
mdj083v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Curigliano, G.
Right arrow Articles by Goldhirsch, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Curigliano, G.
Right arrow Articles by Goldhirsch, A.
Related Collections
Right arrow 2006 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

review

Breast cancer vaccines: a clinical reality or fairy tale?

G. Curigliano1,2,*, G. Spitaleri1,2, E. Pietri1, M. Rescigno3, F. de Braud1,2, A. Cardillo1, E. Munzone1, A. Rocca1, G. Bonizzi3, V. Brichard4, L. Orlando1 and A. Goldhirsch1

1 Department of Medicine, 2 Clinical Pharmacology and New Drugs Development Unit, 3 Division of Experimental Oncology, Laboratory of Experimental Immunology, European Institute of Oncology, Milan, Italy; 4 Cancer Vaccines Program, GlaxoSmithKline Biologicals, Brussels, Belgium

* Correspondence to: Dr. G. Curigliano, Department of Medicine, Clinical Pharmacology Unit, Via Ripamonti 435, 20141 Milano, Italy. Tel: +39-02-57489482; Fax: +39-02-57489581; E-mail: giuseppe.curigliano{at}ieo.it

The characterization of tumor antigens recognized by immune effector cells has opened the perspective of developing therapeutic vaccines in the field of breast cancer. The potential advantages of the vaccines are: (i) the induction of a robust immune response against tumors that are spontaneously weekly immunogenic; (ii) the tumor specificity for some antigens; (iii) the good tolerance and safety profile and (iv) the long-term immune memory, critical to prevent efficiently tumor recurrence. Most trials evaluating breast cancer vaccines have been carried out in patients with extended metastatic breast cancer, characterized by aggressive tumors, resistant to standard cytotoxic treatments, so that clinical efficacy was difficult to achieve. However, some significant immune responses against tumor antigens induced upon vaccinations were recorded. The aim of this review is to analyze the activity of vaccination strategies in current clinical trials. Data of clinical activity have been observed by using vaccines targeting HER2/neu protein, human telomerase reverse transcriptase, carcinoembryonic antigen and carbohydrate antigen given after stem cell rescue. The review discusses possible future directions for vaccine development and applications in the adjuvant setting.

Key words: active immunotherapy, breast cancer, vaccines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. M. Seavey, Z.-K. Pan, P. C. Maciag, A. Wallecha, S. Rivera, Y. Paterson, and V. Shahabi
A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors
Clin. Cancer Res., February 1, 2009; 15(3): 924 - 932.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Ann. Onc., July 1, 2007; 18(7): 1133 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Kitano, S. Kageyama, Y. Nagata, Y. Miyahara, A. Hiasa, H. Naota, S. Okumura, H. Imai, T. Shiraishi, M. Masuya, et al.
HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan
Clin. Cancer Res., December 15, 2006; 12(24): 7397 - 7405.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.